Novel agent abelacimab has potential to be a safer anticoagulant, according to the randomized AZALEA-TIMI 71 trial. The trial had been stopped early because of a surprisingly large reduction in bleeds ...
Abelacimab shows a 62% reduction in major or clinically relevant non-major bleeding compared to rivaroxaban in AFib patients. The study highlights an 89% reduction in gastrointestinal bleeding, a ...
Abelacimab, an FXI inhibitor, significantly reduces bleeding risks in patients on antiplatelet therapy compared with rivaroxaban. The AZALEA-TIMI 71 study demonstrated consistent bleeding reduction ...
MADRID, Spain—Olezarsen (Ionis Pharmaceuticals), an antisense oligonucleotide that targets APOC3 messenger RNA (mRNA), successfully lowers triglyceride levels compared with placebo by 6 months among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results